Vascular endothelial growth factor, left ventricular dysfunction and mortality in hemodialysis patients

Journal of Hypertension

Volumn 26, Issue 9, 2008, Pages 1875-1882

  Mallamaci, Francesca ^a   Benedetto, Francesco A ^a   Tripepi, Giovanni ^a   Cutrupi, Sebastiano ^a   Pizzini, Patrizia ^a   Stancanelli, Benedetta ^b   Seminara, Giuseppe ^b   Bonanno, Graziella ^b   Rapisarda, Francesco ^b   Fatuzzo, Pasquale ^b   Malatino, Lorenzo S ^b   Zoccali, Carmine ^a  

^a CNR Consiglio Nazionale delle Ricerche   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Hemodialysis; Inflammation; Left ventricular systolic dysfunction; Midwall fractional shortening; Mortality; Vascular endothelial growth factor

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERLEUKIN 6; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; UNCLASSIFIED DRUG; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; FEMALE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; AGED; BLOOD; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; DIABETES MELLITUS; FOLLOW UP; MIDDLE AGED; PREVALENCE; RENAL REPLACEMENT THERAPY;

ADULT; AGED; BLOOD PRESSURE; CARDIOMYOPATHIES; COHORT STUDIES; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; RENAL DIALYSIS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENTRICULAR DYSFUNCTION, LEFT;

EID: 57649176588     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328307c3d2     Document Type: Article

References (52)

1. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 1996; 11:1277-1285.
2. Zoccali C. How important is echocardiography for risk stratification in follow-up of patients with chronic kidney disease? Nat Clin Pract Nephrol 2007; 3:178-179.
3. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47:186-192.
4. Stack AG, Bloembergen WE. A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients. Am J Kidney Dis 2001; 38:992-1000.
5. Postorino M, Marino C, Tripepi G, Zoccali C. Prognostic value of the New York Heart Association classification in end-stage renal disease. Nephrol Dial Transplant 2007; 22:1377-1382.
6. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE. Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 2000; 11:912-916.
7. Zoccali C, Benedetto FA, Tripepi G, Mallamaci F, Rapisarda F, Seminara G, et al. Left ventricular systolic function monitoring in asymptomatic dialysis patients: a prospective cohortstudy. J Am Soc Nephrol 2006; 17:1460-1465.
8. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, et al. Prognostic value of echocardiographic indicators of left ventricular systolic function in asymptomatic dialysis patients. J Am Soc Nephrol 2004; 15:1029-1037.
9. Amann K, Breitbach M, Ritz E, Mall G. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 1998; 9:1018-1022.
10. Zoccali C, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Benedetto FA, etal. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 2002; 40:41 -46.
11. Cice G, Ferrara L, Di BA, Russo PE, Marinelli G, Pavese F, et al. Dilated cardiomyopathy in dialysis patients: beneficial effects of carvedilol: a double-blind, placebo-controlled trial. J Am Coll Cardiol 2001; 37:407-411.
12. Drueke T, Fauchet M, Fleury J, Lesourd P, Toure Y, Le PC, et al. Effect of parathyroidectomy on left-ventricular function in haemodialysis patients. Lancet 1980; 1:112-114.
13. Wang AY, Wang M, Woo J, Lam CW, Lui SF, Li PK, et al. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 2004; 15:2186-2194.
14. Ayus JC, Mizani MR, Achinger SG, Thadhani R, Go AS, Lee S. Effects of shortdailyversus conventional hemodialysis on leftventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol 2005; 16:2778-2788.
15. Losito A, Kalidas K, Santoni S, Jeffery S. Association of interleukin- 6-174G/C promoter polymorphism with hypertension and left ventricular hypertrophy in dialysis patients. Kidney Int 2003; 64:616-622.
16. Erten Y, Tulmac M, Derici U, Pasaoglu H, Altok RK, Bali M, et al. An association between inflammatory state and left ventricular hypertrophy in hemodialysis patients. Ren Fail 2005; 27:581-589.
17. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995; 47:884-890.
18. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Cutrupi S, Parlongo S, etal. Fibrinogen, inflammation and concentric left ventricular hypertrophy in chronic renal failure. Eur J Clin Invest 2003; 33:561-566.
19. Nash AD, Baca M, Wright C, Scotney PD. The biology of vascular endothelial growth factor-B (VEGF-B). Pulm Pharmacol Ther 2006; 19:61-69.
20. Freeman AF, Crawford SE, Cornwall ML, Garcia FL, Shulman ST, Rowley AH. Angiogenesis in fatal acute Kawasaki disease coronary artery and myocardium. Pediatr Cardiol 2005; 26:578-584.
21. van Amerongen MJ, Harmsen MC, van Rooijen N, Petersen AH, van Luyn MJ. Macrophage depletion impairs wound healing and increases left ventricular remodeling after myocardial injury in mice. Am J Pathol 2007; 170:818-829.
22. Nakagawa T, Sato W, Sautin YY, Glushakova O, Croker B, Atkinson MA, etal. Uncoupling of vascular endothelial growth factor with nitric oxide as a mechanism for diabetic vasculopathy. J Am Soc Nephrol 2006; 17:736-745.
23. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997; 96:526-534.
24. Ferrari R, Bachetti T, Confortini R, Opasich C, FeboO, Corti A, etal. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995; 92:1479-1486.
25. Chin BS, Blann AD, Gibbs CR, Chung NA, Conway DG, Lip GY. Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. Eur J Clin Invest 2003; 33:941 -948.
26. Amann K, Kronenberg G, Gehlen F, Wessels S, Orth S, Munter K, et al. Cardiac remodelling in experimental renal failure: an immunohistochemical study. Nephrol Dial Transplant 1998; 13:1958-1966.
27. Pawlak K, Pawlak D, Mysliwiec M. Possible new role of monocyte chemoattractant protein-1 in hemodialysis patients with cardiovascular disease. Am J Nephrol 2004; 24:635-640.
28. Stompor T, Zdzienicka A, Motyka M, Dembinska-Kiec A, Davies SJ, Sulowicz W. Selected growth factors in peritoneal dialysis: their relationship to markers of inflammation, dialysis adequacy, residual renal function, and peritoneal membrane transport. Perit Dial Int 2002; 22:670-676.
29. Baylis C. Arginine, arginine analogs and nitric oxide production in chronic kidney disease. Nat Clin Pract Nephrol 2006; 2:209-220.
30. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358:2113-2117.
31. De Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 1995; 25:1056-1062.
32. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, et al. Prognostic impact of the indexation ofleft ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 2001; 12:2768-2774.
33. Shimizu G, Hirota Y, Kita Y, Kawamura K, Saito T, Gaasch WH. Left ventricular midwall mechanics in systemic arterial hypertension. Myocardial function is depressed in pressure-overload hypertrophy. Circulation 1991; 83:1676 -1684.
34. De Simone G, Devereux RB, Roman MJ, Ganau A, Saba PS, Alderman MH, et al. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol 1994; 23:1444-1451.
35. Muiesan ML, Salvetti M, Monteduro C, Rizzoni D, Corbellini C, Castellano M, et al. Changes in midwall systolic performance and cardiac hypertrophy reduction in hypertensive patients. J Hypertens 2000; 18:1651 -1656.
36. Ganau A, Saba PS, Roman MJ, de Simone G, Realdi G, Devereux RB, et al. Ageing induces left ventricular concentric remodelling in normotensive subjects. J Hypertens 1995; 13:1818-1822.
37. Devereux RB, Roman MJ, Palmieri V, Okin PM, Boman K, Gerdts E, et al. Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens 2000; 18:1129-1138.
38. Kraemer HC, Stice E, Kazdin A, Offord D, Kupfer D. How do risk factors work together? Mediators, moderators, and independent, overlapping, and proxy risk factors. Am J Psychiatry2001; 158:848-856.
39. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359:843-845.
40. Li J, Hampton T, Morgan JP, Simons M. Stretch-induced VEGF expression in the heart. J Clin Invest 1997; 100:18-24.
41. Kim CH, Cho YS, Chun YS, Park JW, Kim MS. Early expression of myocardial HIF-1alpha in response to mechanical stresses: regulation by stretch-activated channels and the phosphatidylinositol 3-kinase signaling pathway. Circ Res 2002; 90:E25-E33.
42. Izumiya Y, Shiojima I, Sato K, Sawyer DB, Colucci WS, Walsh K. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 2006; 47:887-893.
43. Da Silva-Azevedo L, Baum O, Zakrzewicz A, Pries AR. Vascular endothelial growth factor is expressed in endothelial cells isolated from skeletal muscles of nitric oxide synthase knockout mice during prazosin-induced angiogenesis. Biochem Biophys Res Commun 2002; 297:1270-1276.
44. Lepic E, Burger D, Lu X, Song W, Feng Q. Lack of endothelial nitric oxide synthase decreases cardiomyocyte proliferation and delays cardiac maturation. Am J Physiol Cell Physiol 2006; 291:C1240-C1246.
45. Nakagawa T, Sato W, Glushakova O, Heinig M, Clarke T, Campbell- Thompson M, et al. Diabetic endothelial nitric oxide synthase knockoutmice develop advanced diabetic nephropathy. J Am Soc Nephrol 2007; 18:539 -550.
46. van den Heuvel AF, van Veldhuisen DJ, van der Wall EE, Blanksma PK, Siebelink HM, Vaalburg WM, et al. Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2000; 35:19 -28.
47. Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005; 16 (Suppl 1):S83-S88.
48. Hilfiker-Kleiner D, Limbourg A, Drexler H. STAT3-mediated activation of myocardial capillary growth. Trends Cardiovasc Med 2005; 15:152 -157.
49. Hilfiker-Kleiner D, Hilfiker A, Fuchs M, Kaminski K, Schaefer A, Schieffer B, et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res 2004; 95:187 -195.
50. Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 2002; 62:339-345.
51. Mathieson PW. How much VEGF do you need? J Am Soc Nephrol 2006; 17:602 -603.
52. Bland JM, Altman DG. Regression towards the mean. BMJ 1994; 308:1499.